0001209191-22-003078.txt : 20220112
0001209191-22-003078.hdr.sgml : 20220112
20220112171402
ACCESSION NUMBER: 0001209191-22-003078
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220110
FILED AS OF DATE: 20220112
DATE AS OF CHANGE: 20220112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bandari Jathin
CENTRAL INDEX KEY: 0001903622
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 22527208
MAIL ADDRESS:
STREET 1: C/O PROTORA THERAPEUTICS, INC.
STREET 2: 345 PARK AVENUE SOUTH, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 204580525
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
BUSINESS PHONE: 646-844-0337
MAIL ADDRESS:
STREET 1: 345 PARK AVENUE SOUTH
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10010
FORMER COMPANY:
FORMER CONFORMED NAME: ArTara Therapeutics, Inc.
DATE OF NAME CHANGE: 20200110
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC
DATE OF NAME CHANGE: 20060420
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2022-01-10
0
0001359931
Protara Therapeutics, Inc.
TARA
0001903622
Bandari Jathin
C/O PROTARA THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK
NY
10010
0
1
0
0
Chief Medical Officer
Common Stock
7500
D
Stock Option (right to buy)
28.20
2030-06-30
Common Stock
14500
D
Stock Option (right to buy)
20.51
2030-08-31
Common Stock
2500
D
Stock Option (right to buy)
19.82
2031-01-18
Common Stock
13877
D
Stock Option (right to buy)
19.82
2031-01-18
Common Stock
11123
D
Stock Option (right to buy)
6.95
2031-09-30
Common Stock
523
D
Stock Option (right to buy)
6.95
2031-09-30
Common Stock
1977
D
Stock Option (right to buy)
7.02
2031-10-31
Common Stock
1355
D
Stock Option (right to buy)
7.02
2031-10-31
Common Stock
5145
D
The shares reported are issued pursuant to a restricted stock unit award (RSU), of which represents a contingent right to receive one share of Issuer's common stock. The RSU vest in equal one-fourth installments on the first, second, third and fourth anniversaries of July 1, 2020.
25% of the shares vest on the one year anniversary of July 1, 2020 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
25% of the shares vest on the one year anniversary of September 1, 2020 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
25% of the shares vest on the one year anniversary of January 19, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
25% of the shares vest on the one year anniversary of October 1, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
25% of the shares vest on the one year anniversary of November 1, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
Mary Grendell, Attorney-in-Fact
2022-01-10
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Blaine Davis, Jesse Shefferman and Mary Grendell, signing individually,
the undersigned's true and lawful attorney-in fact and agent to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of Protara Therapeutics, Inc.
(the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules
thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 30 day of December, 2021.
/s/ Jathin Bandari
Jathin Bandari